Tresiba and Stomatitis - a phase IV clinical study of FDA data

Summary:

Stomatitis is reported as a side effect among people who take Tresiba (insulin degludec), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Novolog, and have Renal cell carcinoma.

The phase IV clinical study analyzes which people have Stomatitis when taking Tresiba. It is created by eHealthMe based on reports of 20,507 people who have side effects when taking Tresiba from the FDA, and is updated regularly.

What is Tresiba?

Tresiba has active ingredients of insulin degludec. It is often used in type 1 diabetes. eHealthMe is studying from 20,677 Tresiba users. Check the latest studies of Tresiba.

What is Stomatitis?

Stomatitis (inflammation of mucous membrane of mouth) is found to be associated with 1,879 drugs and 2,011 conditions by eHealthMe. Check the latest studies of Stomatitis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

20,507 people reported to have side effects when taking Tresiba.
Among them, 50 people (0.24%) have Stomatitis.

Among these 50 people:

How long have people been on Tresiba when they have Stomatitis? *

What is the gender of people who have Stomatitis when taking Tresiba? *

female: 41.3 %
male: 58.7 %

What is the age of people who have Stomatitis when taking Tresiba? *

What are other drugs people take besides Tresiba? *

What are other side effects people have besides Stomatitis? *

Fatigue (feeling of tiredness): 27 people, 54.00%
Diarrhea: 26 people, 52.00%
High Blood Pressure: 22 people, 44.00%
Nausea (feeling of having an urge to vomit): 22 people, 44.00%
Rashes (redness): 15 people, 30.00%
Back Pain: 14 people, 28.00%
Dizziness: 14 people, 28.00%
Abdominal Pain Upper: 13 people, 26.00%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 12 people, 24.00%
Joint Pain: 11 people, 22.00%

What are the existing conditions these people have? *

Renal Cell Carcinoma (a kidney cancer): 15 people, 30.00%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 7 people, 14.00%
Bone Disorder: 7 people, 14.00%
Pancreatic Neuroendocrine Tumor Metastatic: 7 people, 14.00%
Neuroendocrine Tumor: 7 people, 14.00%
Diarrhea: 7 people, 14.00%
Diabetes: 3 people, 6.00%
Stable Angina (a constant chest pain): 3 people, 6.00%
Ovarian Cancer (cancer of ovary): 2 people, 4.00%
Hepatic Cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue): 2 people, 4.00%

* Approximation only. Some reports may have incomplete information.

Do you take Tresiba and have Stomatitis?

- Check whether Stomatitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tresiba:

Tresiba (20,677 reports)

Stomatitis treatments and more:

Stomatitis (75,938 reports)

Browse all side effects of Tresiba:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Stomatitis:

Stomatitis (1,879 drugs)

Browse all the conditions that are associated with Stomatitis:

Stomatitis (2,011 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on insulin degludec (the active ingredients of Tresiba) and Tresiba (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.